A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer

Hansen, 1996, Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer, J Natl Cancer Inst, 88, 668, 10.1093/jnci/88.10.668 Poorter, 1996, Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy, Eur J Cancer, 32A, 2262, 10.1016/S0959-8049(96)00274-2 Schwarz, 2000, Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection, Ann Surg Oncol, 7, 441, 10.1007/s10434-000-0441-y Frank, 2001, Ionic implantation of silicone chronic venous access devices does not alter thrombotic complications: a double-blinded, randomized clinical trial. Surgery, 129, 547 Hartkamp, 2000, Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems, Neth J Med, 57, 215, 10.1016/S0300-2977(00)00083-8 Nightingale, 1997, A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy, Eur J Cancer, 33, 398, 10.1016/S0959-8049(97)89012-0 Verso, 2003, Venous thromboembolism associated with long-term use of central venous catheters in cancer patients, J Clin Oncol, 21, 3665, 10.1200/JCO.2003.08.008 Kuter, 2004, Thrombotic complications of central venous catheters in cancer patients, Oncologist, 9, 207, 10.1634/theoncologist.9-2-207 Payne, 1992, A study of quality of life in cancer patients receiving palliative chemotherapy, Soc Sci Med, 35, 1505, 10.1016/0277-9536(92)90053-S Rischin, 2000, A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis, Med J Aust, 173, 125, 10.5694/j.1326-5377.2000.tb125563.x Wilson, 2002, Patient and carer satisfaction with ‘hospital at home’: quantitative and qualitative results from a randomised controlled trial, Br J Gen Pract, 52, 9 Miwa, 1998, Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue, Eur J Cancer, 34, 1274, 10.1016/S0959-8049(98)00058-6 Schüller, 2000, Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients, Cancer Chemother Pharmacol, 45, 291, 10.1007/s002800050043 Van Cutsem, 2004, Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials, Br J Cancer, 90, 1190, 10.1038/sj.bjc.6601676 Cassidy, 2002, First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin, Ann Oncol, 13, 566, 10.1093/annonc/mdf089 Scheithauer, 2003, Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial, Ann Oncol, 14, 1735, 10.1093/annonc/mdg500 C Twelves, A Wong, M Nowacki et al. Oral capecitabine (Xeloda®) as a replacement for i.v. 5-FU-based adjuvant therapy for colon cancer: efficacy results of a large phase III trial (the X-ACT trial). N Engl J Med; in press. Twelves, 2001, Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma, Eur J Cancer, 37, 597, 10.1016/S0959-8049(00)00444-5 McKendrick, 2004, Capecitabine (X) is resource saving compared with iv bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients Medical resource utilization (MRU) data from a large phase III trial (X-ACT), J Clin Oncol, 22, 264s, 10.1200/jco.2004.22.90140.3578 Douillard, 2004, Pharmacoeconomic analysis of capecitabine in the adjuvant setting Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer, Ann Oncol, 15 James, 2003, Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer, Eur J Cancer, 1, S83, 10.1016/S1359-6349(03)90304-1 Borner, 2002, Schöffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer, Eur J Cancer, 38, 349, 10.1016/S0959-8049(01)00371-9 Liu, 1997, Patient preferences for oral versus intravenous palliative chemotherapy, J Clin Oncol, 15, 110, 10.1200/JCO.1997.15.1.110 Seymour, 2004, Optimising the use and sequencing of fluorouracil irinotecan and oxaliplatin in advanced colorectal cancer (ACRC) The UK MRC FOCUS (CR08) trial, Ann Oncol, 15 Hills, 1979, The two-period cross-over clinical trial, Br J Clin Pharmacol, 8, 7, 10.1111/j.1365-2125.1979.tb05903.x Ward, 1999, Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument, Qual Life Res, 8, 181, 10.1023/A:1008821826499 Twelves, 2002, Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?, Br J Cancer, 86, 1670, 10.1038/sj.bjc.6600341 de Gramont, 1997, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study, J Clin Oncol, 15, 808, 10.1200/JCO.1997.15.2.808 Borras, 2001, Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial, Br Med J, 322, 826, 10.1136/bmj.322.7290.826 King, 2000, Home or hospital? An evaluation of the costs, preferences, and outcomes of domiciliary chemotherapy. Int J Health Serv, 30, 557, 10.2190/CY03-EV15-K38Y-X4AA Deadman, 2001, Taking responsibility for cancer treatment, Soc Sci Med, 53, 669, 10.1016/S0277-9536(00)00369-5